导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 32.93% | 102/4773 |
| 近一周 | 1.02% | 526/5465 |
| 近一月 | -0.55% | 877/5421 |
| 近一季 | -18.95% | 4842/5231 |
| 近半年 | 26.71% | 100/4920 |
| 近一年 | 57.25% | 52/4394 |
| 近两年 | 276.92% | 30/2954 |
| 近三年 | 266.14% | 5/2253 |
| 成立以来 | 198.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.55% 704/4961 |
64.48% 351/5312 |
- - |
- - |
| 2025 | 114.91% 9/4813 |
-6.57% 3368/3635 |
14.39% 44/4076 |
75.38% 10/4524 |
14.66% 81/4813 |
| 2024 | 30.75% 106/3463 |
11.12% 32/2808 |
2.11% 401/3014 |
11.20% 2540/3129 |
3.63% 785/3463 |
| 2023 | 25.35% 12/2656 |
27.01% 89/2280 |
21.52% 3/2385 |
-13.17% 2140/2515 |
-6.46% 1788/2655 |
| 2022 | -25.43% 1317/2207 |
-18.06% 1295/1919 |
2.37% 1307/2016 |
-12.13% 649/2113 |
1.16% 1363/2208 |
| 2021 | 6.74% 509/1822 |
-6.71% 1031/1255 |
6.12% 767/1330 |
-5.95% 881/1466 |
14.64% 68/1822 |
| 2020 | 1.32% 933/1250 |
4.14% 85/1028 |
8.70% 816/1067 |
-3.72% 1097/1164 |
-7.04% 1151/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.04% 755/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证全指通信设备ETF联接C VS. 长安沪深300非周期A(740101) |